Chan Henry Lee Sells 341 Shares of BeOne Medicines (NASDAQ:ONC) Stock

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) SVP Chan Henry Lee sold 341 shares of the business’s stock in a transaction dated Wednesday, March 11th. The stock was sold at an average price of $300.00, for a total transaction of $102,300.00. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Chan Henry Lee also recently made the following trade(s):

• On Wednesday, February 4th, Chan Henry Lee sold 1,660 shares of BeOne Medicines stock. The stock was sold at an average price of $349.52, for a total transaction of $580,203.20.
• On Wednesday, January 7th, Chan Henry Lee sold 664 shares of BeOne Medicines stock. The shares were sold at an average price of $331.76, for a total transaction of $220,288.64.

BeOne Medicines Stock Performance

ONC traded down $1.25 during trading on Friday, reaching $284.05. The company’s stock had a trading volume of 229,085 shares, compared to its average volume of 276,668. The company has a debt-to-equity ratio of 0.22, a quick ratio of 3.08 and a current ratio of 3.41. The company’s fifty day moving average price is $334.52 and its 200-day moving average price is $329.55. BeOne Medicines Ltd. – Sponsored ADR has a 52-week low of $196.45 and a 52-week high of $385.22. The company has a market capitalization of $31.15 billion, a price-to-earnings ratio of 76.49 and a beta of 0.53.

BeOne Medicines (NASDAQ:ONC) last posted its quarterly earnings results on Thursday, February 26th. The company reported $0.58 EPS for the quarter, missing the consensus estimate of $1.60 by ($1.02). BeOne Medicines had a net margin of 5.37% and a return on equity of 10.70%. The business had revenue of $1.50 billion during the quarter, compared to analyst estimates of $1.45 billion. On average, equities analysts forecast that BeOne Medicines Ltd. – Sponsored ADR will post -5.82 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the stock. Wall Street Zen lowered shares of BeOne Medicines from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 28th. Weiss Ratings reiterated a “sell (d-)” rating on shares of BeOne Medicines in a research note on Wednesday, January 21st. Truist Financial boosted their price objective on shares of BeOne Medicines from $400.00 to $412.00 and gave the stock a “buy” rating in a report on Friday, February 27th. Morgan Stanley restated an “overweight” rating and set a $405.00 target price on shares of BeOne Medicines in a research report on Thursday, January 8th. Finally, Barclays lifted their price target on shares of BeOne Medicines from $394.00 to $405.00 and gave the company an “overweight” rating in a research report on Friday, February 27th. Eleven analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $401.00.

Institutional Investors Weigh In On BeOne Medicines

Large investors have recently added to or reduced their stakes in the business. Mariner LLC lifted its holdings in shares of BeOne Medicines by 3.8% in the fourth quarter. Mariner LLC now owns 883 shares of the company’s stock valued at $269,000 after purchasing an additional 32 shares in the last quarter. Signaturefd LLC raised its position in shares of BeOne Medicines by 10.7% during the 4th quarter. Signaturefd LLC now owns 340 shares of the company’s stock worth $103,000 after purchasing an additional 33 shares during the last quarter. Farther Finance Advisors LLC raised its position in shares of BeOne Medicines by 21.8% during the 4th quarter. Farther Finance Advisors LLC now owns 218 shares of the company’s stock worth $66,000 after purchasing an additional 39 shares during the last quarter. CWM LLC lifted its stake in BeOne Medicines by 32.8% in the 4th quarter. CWM LLC now owns 158 shares of the company’s stock valued at $48,000 after buying an additional 39 shares in the last quarter. Finally, Sequoia Financial Advisors LLC lifted its stake in BeOne Medicines by 4.1% in the 3rd quarter. Sequoia Financial Advisors LLC now owns 1,281 shares of the company’s stock valued at $436,000 after buying an additional 50 shares in the last quarter. 48.55% of the stock is owned by institutional investors and hedge funds.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.